CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
843.23MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.4690xvs all stocks
52-Week Change
104.07%vs all stocks
Market Capitalization
843.23MUSDvs all stocks (USD)
Enterprise Value
691.19MUSDvs all stocks (USD)
Forward P/E
-17.63xvs Biotechnology peers
Price to Book (MRQ)
6.65xvs Biotechnology peers
Enterprise to EBITDA
-9.69xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-28.64%vs Biotechnology peers
Return on Equity (TTM)
-81.84%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-71.30MUSDvs all stocks (USD)
Net Income (TTM)
-88.53MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-56.02MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-35.75MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-48.18MUSDvs all stocks (USD)
Pre-tax Income
-38.18MUSDFY2025 · Dec 31, 2025Net Income
-38.18MUSDFY2025 · Dec 31, 2025EBIT
-36.06MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-43.42MUSDFY2025 · Dec 31, 2025Research & Development
30.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
17.77MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-89.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.92MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.12MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-38.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-32.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-32.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
120.15MUSDFY2025 · Dec 31, 2025Interest Paid
1.28MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-38.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
845.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
819.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
802.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-355.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-560.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-560.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
47.95MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
55.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
76.12MSharesUpdated Sep 27, 2026Float Shares
60.22MSharesUpdated Sep 27, 2026Shares Short
12.34MSharesUpdated Sep 27, 2026Short Ratio
9.63daysvs all stocks
Short % of Shares Outstanding
20.74%vs all stocks
% Held by Insiders
14.65%vs all stocks
% Held by Institutions
67.63%vs all stocks
Total Cash (MRQ)
201.56MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.63USDUpdated Sep 27, 2026Total Debt (MRQ)
49.52MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3926xvs Biotechnology peers
Current Ratio (MRQ)
16.09xvs Biotechnology peers
Book Value per Share (MRQ)
1.66USDUpdated Sep 27, 2026Total Assets
125.19MUSDvs all stocks (USD)
Total Current Assets
121.39MUSDFY2025 · Dec 31, 2025Total Liabilities
73.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.81MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
64.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
119.73MUSDFY2025 · Dec 31, 2025Accounts Payable
1.13MUSDFY2025 · Dec 31, 2025Short-term Debt
445.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
89.00KUSDFY2025 · Dec 31, 2025Long-term Debt
48.59MUSDFY2025 · Dec 31, 2025Common Stock (Book)
550.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-230.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
51.92MUSDvs all stocks (USD)
Treasury Stock
448.00KUSDFY2025 · Dec 31, 202552-Week Low
4.35USDUpdated Sep 27, 202652-Week High
14.00USDUpdated Sep 27, 202652-Week Change
104.07%vs all stocks
Beta
-0.4690xvs all stocks
50-Day MA
11.35USDUpdated Sep 27, 2026200-Day MA
7.82USDUpdated Sep 27, 2026Avg 10-Day Volume
1.19MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.30MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.47USDUpdated Sep 27, 2026Other Income / Expense
8.20MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.81
Altman Z-Score 4.46: safe zoneNotable
Altman Z-Score: 4.46
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Avalo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
XGD Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Lingda Group Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets